Brind.

Bank of America upgraded VIR Biotechnology's stock rating, citing its potential in liver therapy.

1 report, 1 independent Updated Aug 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Bank of America VIR Biotechnology

Keep exploring

The entities involved

Bank of America
American multinational banking and financial services corporation
- Goldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Mon 17:24
- Both Bank of America and Deloitte have addressed current treasury management trends.Mon 14:26
VIR Biotechnology
biotech company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 28GuruFocus.comVir Stock Soars After BofA Boosts Rating on Liver Therapy This article first appeared on GuruFocus. Vir Biotechnology (NASDAQ:VIR) jumped more than 12% Tuesday after Bank of America upgraded the stoc